uniQure N.V. (QURE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 38 | 524 | 106 | 16 | 27 | 16 | 19 | 22 |
| Operating profit | $m | -188 | -203 | ||||||
| Net profit | $m | -125 | 330 | -127 | -308 | -240 | -199 | -252 | -225 |
| EPS reported | $ | -3.46 | -4.04 | ||||||
| Operating cashflow per share | $ | -3.09 | -2.43 | ||||||
| Capex per share | $ | 0.01 | 0.00 | ||||||
| FCF per share | $ | -3.09 | -2.43 | ||||||
| Free cash flow | $m | -178 | -161 | ||||||
| Net debt | $m | -96 | -760 | ||||||
| Book value equity | $m | 199 | 324 | ||||||
| Book value per share | $ | 3.46 | 4.89 | ||||||
| Number of shares | m | 57.5 | 66.24 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.92 | 4.25 | ||||||
| P/S LTM | x | 85.48 | 73.69 | ||||||
| P/FCF LTM | x | -7.73 | -8.55 | ||||||
| EV/EBITDA LTM | x | -15.72 | -10.12 | ||||||
| EV/Sales LTM | x | 113.83 | 161.87 | ||||||
| Earnings Yield LTM | % | -14.46% | -7.83% | ||||||
| FCF Yield | % | -12.93% | -11.70% | ||||||
| Quality | |||||||||
| ROE | % | -100.04% | -111.96% | ||||||
| ROIC | % | -24.53% | -22.48% | ||||||
| Operating margin | % | -11.67% | -10.89% | ||||||
| Gross margin | % | +89.53% | +22.79% | ||||||
| FCF/Sales | % | -1105.5% | -862.32% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -40.64% | -31.15% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.33 | -2.56 | ||||||
| Net Debt/EBITDA | x | -3.91 | 1.93 | ||||||
| EBIT/Net interest | x | -3.03 | -3.41 | ||||||
| Net debt/market cap | % | +38.28% | +1.49% | ||||||
| Net debt/Equity | x | -0.48 | -2.35 | ||||||
| Gross debt/equity | x | 2.70 | 0.19 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free